ACP-103: Phase II data

In an intent-to-treat analysis of 376 evaluable patients in a Phase II trial, ACP-103 met the primary endpoint of a significant reduction of psychosis

Read the full 244 word article

How to gain access

Continue reading with a
two-week free trial.